Rubedo collaborates with Cedars-Sinai on senolytic IPF program

Latest articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

X marks the spot for meaningful information on aging and cognition

Understanding chromosomal differences between men and women could be the X Factor when it comes to tackling cognitive decline. A new paper published in Jama...

Most read

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Editor's picks

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

Click the globe for translations.

Senolytic start-up establishes collaboration with Cedars-Sinai Medical Center to advance idiopathic pulmonary fibrosis program.

Silicon Valley start-up Rubedo Life Sciences today announced a collaboration with Cedars-Sinai Medical Center in Los Angeles, to advance its idiopathic pulmonary fibrosis (IPF) senolytic theraputics program and establish collaborative studies. As part of the collaboration, Dr Cory Hogaboam, professor of medicine and research scientist at Cedars-Sinai will be joining Rubedo’s Scientific Advisory Board.

Longevity.Technology: Affecting around 100,000 people in the US, IPF is a rare, but serious lung disease that causes a build-up of scar tissue in the lungs. When we spoke with Rubedo earlier this year, CEO Dr Marco Quarta expressed concern that the COVID-19 pandemic may lead to a surge in IPF cases, and that he hoped to bring a therapeutic to the clinic “as soon as possible”.

Rubedo’s main program targets senescent cells, which accumulate in multiple tissues in our bodies as we age and promote inflammation, fibrosis and cancer. Cellular senescence is a master regulator of aging and drives many age-related diseases.

Marco Quarta
CEO, Rubedo Life Sciences, Dr Marco Quarta

“Rubedo’s strategy for entry into the longevity space is a senolytic program, targeting the pro inflammatory and pro fibrotic senescent cells,” said Quarta in a statement. “Our first clinical program will be IPF, which is an unmet medical need and we look forward to working with Cedars Sinai Medical Center.”

Taking senolytics to the clinic

Commenting on today’s news, Quarta told us, “Together with the team at Cedars-Sinai we are building an innovative pipeline that will allow to solidly advance Rubedo’s therapeutic discovery program for IPF into the clinic.

Ovarian Longevity webinar

“We are excited to work with world-class experts in interstitial lung diseases at Cedars-Sinai. In particular, Professor Hogaboam is a fantastic advisor and collaborator. He brings a deep understanding of IPF pathology, the clinical landscape but also of cellular senescence and its role in IPF disease.”

Unique among senolytic therapies

Dr Hogaboam’s distinguished career encompasses more than 20 years of scientific experience and he is also an adjunct professor of pathology at the University of Michigan Medical School.

“I joined forces advising and collaborating with Rubedo because throughout my career working on IPF, I came to the conclusion that targeting cellular senescence is the only way to unlock a possible cure for this devastating age-related disease,” he said. “Among all the proposed senolytic therapies, Rubedo has a unique platform that promises to successfully deliver an effective pharmacological treatment for IPF.”

Rubedo’s proprietary Alembic drug discovery platform combines computational and chemistry proprietary technologies to generate novel prodrugs that selectively target multiple pathologic cell types (including rare cell types) driving age-related diseases.

Ovarian Longevity webinar

Intrigued by the exciting and developing senotherapeutics field? Our market intelligence report on senotherapeutics is now available – order your copy here and watch out for more senotherapeutics-related articles coming soon.

Image courtesy of Rubedo Life Sciences
Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...

Related articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Fauna closes $9 million to expand drug discovery platform

Leveraging animal genomics to improve human health, Fauna Bio set to expand its comparative genomics platform for novel target drug discovery. Silicon Valley biotech startup...

Smartphone-sized bioartificial kidney prototype passes key test

The Kidney Project successfully tests a prototype bioartificial kidney and wins KidneyX’s $650,000 Artificial Kidney Prize. The Kidney Project’s implantable bioartificial kidney, one that promises...

Shifting gear: startup aims to de-risk rejuvenation therapy

Shift Bioscience raising funding to develop safe cellular reprogramming therapies for rejuvenation. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the...

Senolytic cocktail reduces aging-associated disc degeneration

Senolytic drug therapies that target aging cells early pave the way to easing back pain. New findings, reported in Nature Communications, show how a novel...
Nutriop